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At Risk for Huntington's Disease
HD is a genetically caused brain disorder that causes uncontrollable bodily movements and robs
people's ability to walk, talk, eat, and think. The final result is a slow, ugly death. Children of parents
with HD have a 50-50 chance of inheriting the disease. There is no cure or treatment.
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FRIDAY, MARCH 02, 2018

The best news for the Huntington's disease
community since the discovery of the gene: Ionis trial
data revealed, Roche confirms jump to Phase 3
Researchers revealed impressive, if not conclusive, additional information at
CHDI Foundation's 13th Annual Huntington’s Disease Therapeutics Conference
yesterday regarding the historic Ionis HD clinical trial: the drop in mutant protein
observed in the cerebral spinal fluid (CSF) of participants corresponds to as much
as an 85 percent decrease in the cortex of the brain, head physician Dr. Sarah
Tabrizi announced.
It’s the best news the HD community has received since the publication of the
research confirming the discovery of the gene 25 years ago this month. As
scientists have observed, it’s also a major step for disease and drug research in
general.
“The magnitude of mutant huntingtin [protein] reduction observed exceeds the
effect needed for disease modification in animal models,” Dr. Tabrizi, of
University College of London (the lead clinical trial site), told an audience of
some 350 scientists, drug company representatives, and HD advocates at the
conference in Palm Springs, CA.
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Dr. Sarah Tabrizi presenting the IONIS-HTTRx trial data on March 1, 2018
(photo by Gene Veritas, aka Kenneth P. Serbin)
Ionis officials announced in December that the Phase 1/2a trial for the genesilencing drug IONIS-HTTRx “substantially exceeded our expectations” in safely
reducing the mutant huntingtin in the CSF.
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For the first time, Dr. Tabrizi’s presentation (plus an Ionis press release) specified
the level of huntingtin reduction.
During the clinical trial, participants received the drug via spinal injections, and
doctors measured the drug’s ability to reduce the protein by extracting CSF
samples.
IONIS-HTTRx lowered mutant huntingtin an average of 40 percent, with a
maximum reduction of 60 percent. As Dr. Tabrizi explained, projecting from the
numerous, painstaking animal studies done by Ionis, the reductions in the cortex
range from 55-85 percent.
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Frank Bennett, Ph.D., Ionis senior vice president of research and the franchise
leader for neurology programs (left) and Anne Smith, Ph.D., Ionis director of
clinical development (middle), confer with Dr. Tabrizi moments before the two
women's historic presentation of the IONIS-HTTRx trial data. Dr. Bennett led the
Ionis efforts to develop the drug (photo by Gene Veritas).
The cortex – along with the striatum, which is critical to motor control and
managing the reward system – is the area of the brain most affected by HD. It is
the most developed area of the brain, the source of thought and language, abilities
severely hampered by HD.
Watch Dr. Tabrizi in the short video excerpts below explain this data and thank the
46 brave clinical trial volunteers and the many others involved in the effort. I also
recommend watching the full video – which includes further trial data and a
helpful overview of the project by Anne Smith, Ph.D., of Ionis – by clicking here.
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Ionis trial reduces bad
Huntington's disease protein
from Gene Veritas

06:29

Ionis
trial reduces bad Huntington's disease protein from Gene Veritas on
Vimeo.
The plans for RG6042, the drug’s new name
The presentation by Drs. Smith and Tabrizi – the first public presentation of the
trial data – can perhaps help inspire the HD community and researchers to become
engaged in the next, crucial step: testing the drug’s efficacy.
Based on its partnership agreement with Ionis, Swiss pharmaceutical giant Roche,
which now holds the license to the drug, will carry out a longer trial with
hundreds of participants, including sites in the U.S.
The main question: will symptoms of this progressive, deadly disease stabilize, or
even be reversed?
In an interview at the conference, Roche officials told me that – as Ionis had
indicated – the company would take the unusual step of skipping a Phase 2 trial
(testing efficacy for the first time) and going directly to a Phase 3 (confirming
efficacy in hundreds, or more, participants).
They pointed to the excellent results of the Phase 1/2a trial; Ionis’ superb
development of the drug; the nonprofit CHDI’s expertise and leadership; and the
enthusiasm from – and urgent need of – the HD community.
Roche has officially changed the name of IONIS-HTTRx to RG6042. “R” stands
for Roche, and “G” for Genentech, a major U.S.-based pharmaceutical company
acquired by Roche in 2009 for $46.8 billion. The number 6042 is a standard drug
number assigned by the company. If Phase 3 is successful, a drug issued for
commercial sale will get a brand name.
All U.S-based Roche personnel and products still use the name Genentech.
Roche has not yet determined a start date or timeline for Phase 3. I will provide a
detailed report on the interview and Roche’s plans, and also my personal reactions
to the conference, in upcoming articles.
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Members of the Roche HD clinical trial team watch Dr. Tabrizi's presentation.
From left to right, Scott Schobel, M.D., M.S., clinical science leader of product
development; Lauren Boak, Ph.D., global development team leader; Erik
Lundgren, lifecycle leader of the HD program; and Mai-Lise Nguyen, the patient
partnership director for the HD program (photo by Gene Veritas).
Time for excitement, but also caution
CHDI Chief Scientific Officer Robert Pacifici, Ph.D., called the results of the
Ionis trial “incredibly exciting.”
However, he also cautioned the HD community.
“Drug discovery is a really time-consuming and inefficient process, and, sadly,
fraught with many failures,” Dr. Pacifici said. “The first time you put something
into people, no matter how prepared, you never know whether it’s going to be safe
and well-tolerated. What the initial trial showed was that at those doses, with the
route of delivery, with that population of folks, it is indeed safe and well-tolerated.
(If it wasn’t, it would stop in its tracks.) Once you get to this stage, a lot of the
uncertainty about timelines goes away.
“This is really the time to be incredibly careful and incredibly deliberate. It’s
going to take a while now to orchestrate the Phase 3 trial. That’s the pivotal trial
that tells you whether or not the drug works.”
Everything needs to be done “by the book” to get a really “conclusive result,” he
added.
If the trial fails, it will still provide scientists and physicians with guideposts for
future research and trials, he said.
“We owe a huge debt of gratitude to those patients who signed up for that initial
trial,” Dr. Pacifici concluded. “It’s going to require not only more of that type of
participation, but a lot of patience.”
You can watch my interview with Dr. Pacifici about the conference and the Ionis
trial in the video below.
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A time for excitement, but
also great care and deliberation
from Gene Veritas

30:55

A time
for excitement, but also great care and deliberation from Gene Veritas on Vimeo.
***
Ionis hosted a live webcast at 11 a.m. Eastern Time today. A webcast replay,
including slides with clinical trial data, are available by clicking here.
For detailed coverage of the HD conference presentations, visit hdbuzz.net.
Visit my Vimeo album, to be periodically updated in the coming weeks, for other
presentations and interviews at the conference.
(Disclosure: I hold a symbolic amount of Ionis shares.)
Posted by Gene Veritas at 5:09 PM
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